Protara Therapeutics (TARA) Change in Account Payables (2019 - 2026)

Protara Therapeutics (TARA) has 8 years of Change in Account Payables data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 172.41% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 28.45% increase from a year earlier, with the FY2025 full-year figure at -$873000.0, down 163.22% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.1 million, up from -$1.6 million in the prior quarter.
• Over the last five years, Change in Account Payables for TARA reached as high as $3.0 million in Q2 2025 and fell as low as -$2.2 million in Q2 2023.
• Historically, Change in Account Payables has averaged $180941.2 across 5 years, with a median of $64000.0 in 2022.
• Across the five-year window, Change in Account Payables soared 4242.31% in 2022 and slumped 1395.97% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at $1.1 million in 2022, then tumbled by 106.2% to -$70000.0 in 2023, then soared by 2271.43% to $1.5 million in 2024, then plunged by 202.76% to -$1.6 million in 2025, then soared by 169.72% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $1.1 million in Q1 2026, -$1.6 million in Q4 2025, and -$795000.0 in Q3 2025.